Tell me about biomarkers that are relevant
There are several important biomarkers that are relevant for breast cancer diagnosis, treatment planning, and prognosis. According to the American Cancer Society, the three main biomarkers currently used in breast cancer care are:
-
Hormone Receptors (ER/PR): Estrogen receptor (ER) and progesterone receptor (PR) status indicates if the cancer's growth is supported by hormones. ER/PR+ cancers can be treated with hormone therapy. About 70-80% of breast cancers are ER/PR+.
-
HER2 Status: Human epidermal growth factor receptor 2 (HER2) is a protein that promotes cancer cell growth. HER2+ cancers can be treated with targeted drugs. About 10-20% of breast cancers are HER2+.
-
Ki-67: This protein is a marker of how fast cancer cells are growing and dividing. High Ki-67 levels are associated with more aggressive cancers. This marker helps determine prognosis and treatment approach.
The NCCN Guidelines for Breast Cancer also highlight some emerging biomarkers:
- PIK3CA gene mutations: May predict response to some targeted therapies
- PD-L1: An immune system biomarker that may indicate potential for immunotherapy
- Tumor mutational burden (TMB): High TMB may predict immunotherapy response
Multigene panel tests are also now used to analyze a range of genes to help refine prognosis and guide treatment decisions for some patients.
It's important to discuss the role of biomarker testing in your individual situation with your oncology team. Biomarker status, along with other factors like cancer stage and your overall health, help personalize treatment planning.
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Grounded in NCCN Guidelines for Patients: Invasive Breast Cancer — the same guidelines oncologists use.
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated October 15, 2025. Informational only — not a substitute for your oncology team.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Source Guidelines
NCCN Guidelines for Patients: Invasive Breast Cancer (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with diagnosis for Breast Cancer patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about Breast Cancer
- What are the key biomarkers in breast cancer
- What biomarker tests are recommended for Breast Cancer
- What does circulating tumor DNA (ctDNA) testing tell me about my Breast Cancer
- What biomarkers predict Breast Cancer recurrence risk
- What do ER, PR, and HER2 biomarker tests mean in breast cancer
- What biomarker testing is recommended for locally advanced Breast Cancer
- What are my initial treatment options for Breast Cancer, and should targeted or immunotherapy based on biomarkers...
- What steps do I need to take to prepare for the biomarker testing process? Is there anything I should avoid before...